Changes of dopamine transporter availability in depressed patients with and without anhedonia: A I-N-ω-fluoropropyl-carbomethoxy-3β- (4-iodophenyl)tropane SPECT study

Neuropsychobiology

Volumn 70, Issue 4, 2014, Pages 235-243

  Camardese, Giovanni ^a   De Risio, Luisa ^a   Di Nicola, Marco ^a   Pucci, Lorella ^a   Cocciolillo, Fabrizio ^a   Bria, Pietro ^a   Giordano, Alessandro ^a   Janiri, Luigi ^a   Di Giuda, Daniela ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

123I N fluoropropyl carbomethoxy 3 (4 iodophenyl)tropane; Dopamine transporter; Major depression; Single photon emission computed tomography

Indexed keywords

AMISULPRIDE; DOPAMINE TRANSPORTER; N OMEGA FLUOROPROPYL CARBOMETHOXY 3BETA (4 IODOPHENYL)TROPANE I 123; RADIOPHARMACEUTICAL AGENT; TROPANE DERIVATIVE; UNCLASSIFIED DRUG; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; RADIOACTIVE IODINE;

ADULT; ANHEDONIA; ARTICLE; ASSESSMENT OF HUMANS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG BINDING; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; MALE; MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOMETRY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SNAITH HAMILTON PLEASURE SCALE; SPECT SCANNER; TREATMENT DURATION; TREATMENT OUTCOME; COMPLICATION; DEPRESSION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SCINTISCANNING;

ADULT; ANHEDONIA; CORPUS STRIATUM; DEPRESSIVE DISORDER; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 84925131435     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000368117     Document Type: Article

References (59)

1. Schildkraut JJ: The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J of Psychiatry 1965; 122: 509-522.
2. Brown AS, Gershon S: Dopamine and depression. J Neural Transm Gen Sect 1993; 91: 75-109.
3. Dunlop BW, Nemeroff CB: The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007; 64: 327-337.
4. Cummings JL: Depression and Parkinson's disease: a review. Am J Psychiatry 1992; 149: 443-454.
5. Volkow ND: The reality of comorbidity: depression and drug abuse. Biol Psychiatry 2004; 56: 714-717.
6. Ashby FG, Isen AM, Turken AU: A neuropsychological theory of positive affect and its influence on cognition. Psychol Rev 1999; 106: 529-550.
7. Nieoullon A: Dopamine and the regulation of cognition and attention. Progr Neurobiol 2002; 67: 53-83.
8. Assadi SM, Yucel M, Pantelis C: Dopamine modulates neural networks involved in effortbased decision-making. Neurosci Biobehav Rev 2009; 33: 383-393.
9. Stein DJ: Depression, anhedonia, and psychomotor symptoms: The role of dopaminergic neurocircuitry. CNS Spectr 2008; 13: 561-565.
10. Blackburn JR, Pfaus JG, Phillips AG: Dopamine functions in appetitive and defensive behaviours. Progr Neurobiol 1992; 39: 247-279.
11. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, ed 4, text revision. Washington, American Psychiatric Association, 2000.
12. Willner P, Hale AS, Argyropoulos S: Dopaminergic mechanism of antidepressant action in depressed patients. J Affect Disord 2005; 86: 37-45.
13. Isella V, Iurlaro S, Piolti R, Ferrarese C, Frattola L, Appollonio I, Melzi P, Grimaldi M: Physical anhedonia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003; 74: 1308-1311.
14. Salamone JD, Correa M, Farrar A, Mingote SM: Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology (Berl) 2007; 191: 461-482.
15. Treadway MT, Zald DH: Reconsidering anhedonia in depression: Lessons from translational neuroscience. Neurosci Biobehav Rev 2011; 35: 537-555.
16. Nutt DJ: The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry 2006; 67(suppl 6): 3-8.
17. Nikolaus S, Antke C, Beu M, Kley K, Larisch R, Wirrwar A, Müller HW: In-vivo quantification of dose-dependent dopamine transporter blockade in the rat striatum with small animal SPECT. Nucl Med Commun 2007; 28: 207-213.
18. Frazer A, Gerhardt GA, Daws LC: New views of biogenic amine transporter function: implications for neuropsychopharmacology. Int J Neuropsychopharmacol 1999; 2: 305-320.
19. Laine TP, Ahonen A, Rasanen P, Tiihonen J: Dopamine transporter availability and depressive symptoms during alcohol withdrawal. Psychiatry Res 1999; 90: 153-157.
20. Meyer JH, Kruger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A, Minifie C, Houle S, Hussey D, Kennedy SH: Lower dopamine transporter binding potential in striatum during depression. Neuroreport 2001; 12: 4121-4125.
21. Neumeister A, Willeit M, Praschak-Rieder N, Asenbaum S, Stastny J, Hilger E, Pirker W, Konstantinidis A, Kasper S: Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychol Med 2001; 31: 1467-1473.
22. Wu H, Lou C, Huang Z, Shi G: SPECT imaging of dopamine transporters with (99m)Tc-TRODAT-1 in major depression and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2011; 23: 63-67.
23. Brunswick DJ, Amsterdam JD, Mozley PD, Newberg A: Greater availability of brain dopamine transporters in major depression shown by [ 99m Tc]TRODAT-1 SPECT imaging. Am J Psychiatry 2003; 160: 1836-1841.
24. Amsterdam JD, Newberg AB: A preliminary study of dopamine transporter binding in bipolar and unipolar depressed patients and healthy controls. Neuropsychobiology 2007; 55: 167-170.
25. Amsterdam JD, Newberg AB, Soeller I, Shults J: Greater striatal dopamine transporter density may be associated with major depressive episode. J Affect Disord 2012; 141: 425-431.
26. Yang YK, Yeh TL, Yao WJ, Lee IH, Chen PS, Chiu NT, Lu RB: Greater availability of dopamine transporters in patients with major depression-a dual-isotope SPECT study. Psychiatry Res 2008; 162: 230-235.
27. Sarchiapone M, Carli V, Camardese G, Cuomo C, Di Giuda D, Calcagni ML, Focacci C, De Risio S: Dopamine transporter binding in depressed patients with anhedonia. Psychiatry Res 2006; 147: 243-248.
28. Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ, Schoemaker H: Amisulpride: from animal pharmacology to therapeutic action. Int Clin Psychopharmacol 1997; 12(suppl 2):S29-S36.
29. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P: A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 1995; 167: 99-103.
30. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(suppl 20): 22-33, quiz 34-57.
31. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
32. Lecrubier Y, Boyer P, Turjanski S, Rein W: Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride study group. J Affect Disord 1997; 43: 95-103.
33. Cassano GB, Jori MC, Group A: Efficacy and safety of amisulpride 1 mg versus paroxetine 1 mg in major depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 2002; 17: 27-32.
34. Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, Nagren K, Nobili F, Walker Z, Van Laere K: EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging 2010; 37: 443-450.
35. Kretschmann H-J, Weinrich W: Neuroanatomy and Cranial Computed Tomography. Stuttgart, Thieme, 1986.
36. Camardese G, Di Giuda D, Di Nicola M, Cocciolillo F, Giordano A, Janiri L, Guglielmo R: Imaging studies on dopamine transporter and depression: a review of literature and suggestions for future research. J Psychiatr Res 2014; 51: 7-18.
37. Kim CH, Cheon KA, Koo MS, Ryu YH, Lee JD, Chang JW, Lee HS: Dopamine transporter density in the basal ganglia in obsessivecompulsive disorder, measured with [123I] IPT SPECT before and after treatment with serotonin reuptake inhibitors. Neuropsychobiology 2007; 55: 156-162.
38. Tiihonen J, Kuikka J, Bergstrom K, Lepola U, Koponen H, Leinonen E: Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry 1997; 154: 239-242.
39. Weintraub D, Newberg AB, Cary MS, Siderowf AD, Moberg PJ, Kleiner-Fisman G, Duda JE, Stern MB, Mozley D, Katz IR: Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. J Nucl Med 2005; 46: 227-232.
40. Di Giuda D, Camardese G, Bentivoglio AR, Cocciolillo F, Guidubaldi A, Pucci L, Bruno I, Janiri L, Giordano A, Fasano A: Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging 2012; 39: 1937-1948.
41. Laasonen-Balk T, Kuikka J, Viinamaki H, Husso-Saastamoinen M, Lehtonen J, Tiihonen J: Striatal dopamine transporter density in major depression. Psychopharmacology (Berl) 1999; 144: 282-285.
42. Klimek V, Schenck JE, Han H, Stockmeier CA, Ordway GA: Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiatry 2002; 52: 740-748.
43. Klimke A, Larisch R, Janz A, Vosberg H, Muller-Gartner HW, Gaebel W: Dopamine D2 receptor binding before and after treatment of major depression measured by [123I] IBZM SPECT. Psychiatry Res 1999; 90: 91-101.
44. Laasonen-Balk T, Viinamaki H, Kuikka JT, Husso-Saastamoinen M, Lehtonen J, Tiihonen J: 123I-beta-CIT binding and recovery from depression. A six-month follow-up study. Eur Arch Psychiatry Clin Neurosci 2004; 254: 152-155.
45. Wu CK, Chin Chen K, See Chen P, Chiu NT, Yeh TL, Lee IH, Yang YK: No changes in striatal dopamine transporter in antidepressant-treated patients with major depression. Int Clin Psychopharmacol 2013; 28: 141-144.
46. Hsieh PC, Lee IH, Yeh TL, Chen KC, Huang HC, Chen PS, Yang YK, Yao WJ, Lu RB, Chiu NT: Distribution volume ratio of serotonin and dopamine transporters in euthymic patients with a history of major depression-a dual-isotope SPECT study. Psychiatry Res 2010; 184: 157-161.
47. Gordon I, Weizman R, Rehavi M: Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol 1996; 298: 27-30.
48. Kilbourne EJ, Nankova BB, Lewis EJ, McMahon A, Osaka H, Sabban DB, Sabban EL: Regulated expression of the tyrosine hydroxylase gene by membrane depolarization. Identification of the responsive element and possible second messengers. J Biol Chem 1992; 267: 7563-7569.
49. Newberg A, Amsterdam J, Shults J: Dopamine transporter density may be associated with the depressed affect in healthy subjects. Nucl Med Commun 2007; 28: 3-6.
50. Drevets WC: Neuroimaging studies of mood disorders. Biol Psychiatry 2000; 48: 813-829.
51. Aan het Rot M, Mathew SJ, Charney DS: Neurobiological mechanisms in major depressive disorder. CMAJ 2009; 180: 305-313.
52. Elovainio M, Jokela M, Kivimaki M, Pulkki-Raback L, Lehtimaki T, Airla N, Keltikangas-Jarvinen L: Genetic variants in the DRD2 gene moderate the relationship between stressful life events and depressive symptoms in adults: cardiovascular risk in young Finns study. Psychosom Med 2007; 69: 391-395.
53. Price J, Cole V, Goodwin GM: Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry 2009; 195: 211-217.
54. Spijker J, Bijl RV, de Graaf R, Nolen WA: Determinants of poor 1-year outcome of DSMIII-R major depression in the general population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatr Scand 2001; 103: 122-130.
55. Rado S: Psychoanalysis of Behavior. Collected Papers. New York, Grune & Stratton, 1962.
56. Meehl PE: Psychodiagnosis. Selected Papers. Minneapolis, University of Minnesota Press, 1973.
57. Di Nicola M, De Risio L, Battaglia C, Camardese G, Tedeschi D, Mazza M, Martinotti G, Pozzi G, Niolu C, Di Giannantonio M, Siracusano A, Janiri L: Reduced hedonic capacity in euthymic bipolar subjects: a trait-like feature? J Affect Disord 2012; 147: 446-450.
58. Cortes R, Soriano E, Pazos A, Probst A, Palacios JM: Autoradiography of antidepressant binding sites in the human brain: localization using [3H]imipramine and [3H]paroxetine. Neuroscience 1988; 27: 473-496.
59. Ziebell M, Holm-Hansen S, Thomsen G, Wagner A, Jensen P, Pinborg LH, Knudsen GM: Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I. J Nucl Med 2010; 51: 1885-1891.